Collins said he thinks that testing a vaccine in at least 10,000 people could potentially give enough evidence of safety and efficacy to clear it for wider use. The late-stage vaccine trials launched so far in the U.S. aim to recruit up to 30,000 people. (Reporting by Carl Oâ€™Donnell in New York and Mrinalika Roy in Bengaluru; Editing by Leslie Adler) Please note you must be a Maverick Insider to comment. Sign up here or sign in if you are already an Insider.